Treatment Algorithms: Non-Small Cell Lung Cancer - Molecular profiling will increasingly guide the choice of therapy
NEW YORK, Nov. 13, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Treatment Algorithms: Non-Small Cell Lung Cancer – Molecular profiling will increasingly guide the choice of therapyhttp://www.reportlinker.com/p01037160/Treatment-Algorithms-Non-Small-Cell-Lung-Cancer-–--Molecular-profiling-will-increasingly-guide-the-choice-of-therapy.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
•Catalyst•Summary
EXECUTIVE SUMMARY•Strategic scoping and focus•Datamonitor key findings
DISEASE DEFINITION AND DIAGNOSIS•Disease definition - Non-small cell lung cancer is the most common type of lung cancer - Lung cancer is the leading cause of cancer-related death
•Etiology
- Tobacco smoke is the main risk factor for lung cancer
- Environmental factors may also influence lung cancer risk
- Current screening methods do not improve survival
•Symptoms•Prognosis - Late presentation and diagnosis contribute to poor survival rates
•Presentation and diagnosis - Asymptomatic nature of early-stage disease delays time to initial presentation
•Influences on diagnosis and treatment rates - "Be clear on cancer" campaign- "Tips from former smokers" campaign
•Referral patterns - Referral is dictated by stage at diagnosis and treatment approach
PATIENT SEGMENTATION•Stage distribution - Extensive use of the American Joint Committee on Cancer TNM classification system
CURRENT TREATMENT OPTIONS•Stage I–III - Treatment type
•Stage IV - Treatment and prescribing trends: first-line therapy- Treatment and prescribing trends: maintenance therapy - Treatment and prescribing trends: second-line therapy - Treatment and prescribing trends: third-line therapy
•Local relapse - Treatment and prescribing trends: local relapse
•Distant relapse - Treatment and prescribing trends: first-line therapy - Treatment and prescribing trends: second-line therapy - Treatment and prescribing trends: third-line therapy
•Future changes in therapy - Mutation testing will increasingly guide the choice of therapy
- Targeted therapies will continue to be the focus of drug development
- Companion diagnostics will be further integrated into drug development and clinical practice
BIBLIOGRAPHY•Journal papers•Websites•Datamonitor reports•Other
APPENDIXA•Physician data
TABLES•Table: NSCLC 5-year survival rates, by stage at diagnosis, 2002–08•Table: Leading treatments for NSCLC across the seven major markets, 2012 •Table: Survey respondents across the seven major markets, by country and physician type, 2012
FIGURES•Figure: Distribution of NSCLC patients by stage of disease in each of the seven major markets, 2012 •Figure: Top three therapeutic strategies used in the treatment of Stage IA–Stage IIIB NSCLC across the seven major markets, 2012•Figure: Uptake of neoadjuvant and adjuvant chemotherapy in patients with Stage IIIA disease whose treatment plan includes surgery and chemotherapy •Figure: Top three chemotherapy regimens used in the adjuvant treatment of Stage IIIA NSCLC in each of the seven major markets, 2012 •Figure: Top three chemotherapy regimens used in the neoadjuvant treatment of Stage IIIA NSCLC in each of the seven major markets, 2012 •Figure: Top three therapeutic strategies used in the treatment of Stage IV NSCLC in each of the seven major markets, 2012•Figure: Top three chemotherapy regimens used in the first-line treatment of Stage IV NSCLC in each of the seven major markets, 2012•Figure: Percentage of Stage IIIB–IV NSCLC patients who are tested for EGFR mutations, EML4-ALK gene rearrangements, and KRAS mutations in each of the seven major markets, 2012 •Figure: Uptake of the Avastin-carboplatin-paclitaxel regimen in the first-line treatment of Stage IV NSCLC in each of the seven major markets, 2012•Figure: Uptake of Tarceva and Iressa in the first-line treatment of Stage IV NSCLC in each of the seven major markets, 2012•Figure: Use of maintenance therapy in Stage IV NSCLC in each of the seven major markets, 2012•Figure: Top three maintenance therapies used in Stage IV NSCLC in each of the seven major markets, 2012•Figure: Percentage of Stage IV NSCLC patients receiving second- and third-line chemotherapy in each of the seven major markets, 2012 •Figure: Top three therapies used in the second-line treatment of Stage IV NSCLC in each of the seven major markets, 2012•Figure: Top three therapies used in the third-line treatment of Stage IV NSCLC in each of the seven major markets, 2012•Figure: Percentage of Stage I–IIIB NSCLC patients who relapse with local and distant disease in each of the seven major markets, 2012 •Figure: Top three therapeutic strategies used in the treatment of Stage I–IIIB NSCLC patients who relapse with local disease in each of the seven major markets, 2012•Figure: Top three therapeutic strategies used in the treatment of Stage I–IIIB NSCLC patients who relapse with distant disease in each of the seven major markets, 2012•Figure: Top three chemotherapy regimens used in the first-line treatment of Stage I–IIIB patients who relapse with distant disease in each of the seven major markets, 2012 •Figure: Percentage of distant relapse NSCLC patients receiving second- and third-line chemotherapy in each of the seven major markets, 2012 •Figure: Top three therapies used in the second-line treatment of distant relapse NSCLC patients in each of the seven major markets, 2012•Figure: Top three therapies used in the third-line treatment of distant relapse NSCLC patients in each of the seven major markets, 2012
Companies Mentioned To order this report:Pathology Industry: Treatment Algorithms: Non-Small Cell Lung Cancer – Molecular profiling will increasingly guide the choice of therapyContact
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article